SCHEMBL5763313

SCHEMBL5763313

Cc1nc(Cc2ccccc2F)sc1C1CCNCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 7/20 0.43
SLC6A3 Q01959 6/20 0.43
SLC6A4 P31645 6/20 0.43
HTR1A P08908 5/20 0.43
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HTR2C P28335 3/20 0.39
HTR2B P41595 1/20 0.39
P2RX7 Q99572 1/20 0.37
HTR6 P50406 2/20 0.37
PIK3CD O00329 1/20 0.36
PIK3C2B O00750 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
CCNT1 O60563 1/20 0.36
CDK9 P50750 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5762632 0.87 SLC6A2 (0.41) SLC6A2SLC6A3SLC6A4HTR1AMEN1
SCHEMBL5766631 0.85 HTR6 (0.50) SLC6A2SLC6A3SLC6A4HTR1AHTR6
SCHEMBL5762674 0.85 GPR52 (0.43) SLC6A2SLC6A3SLC6A4HTR1AMEN1
SCHEMBL5762609 0.82 GABRA1 (0.50) SLC6A2SLC6A3SLC6A4HTR1AMEN1
Hydrochloric Acid SCHEMBL5765809 0.81 GABRA1 (0.49) SLC6A2SLC6A3SLC6A4HTR1AMEN1
SCHEMBL5763769 0.80 PLAT (0.41) SLC6A2SLC6A3SLC6A4HTR1AMEN1
SCHEMBL5762754 0.79 HTR6 (0.47) SLC6A2SLC6A3SLC6A4HTR1AMEN1
SCHEMBL5765101 0.78 HTR6 (0.50) SLC6A2SLC6A3SLC6A4HTR2CHTR2B
SCHEMBL5766897 0.78 SLC6A2 (0.49) SLC6A2SLC6A3SLC6A4HTR1AMEN1
SCHEMBL5765079 0.77 HTR6 (0.38) MEN1KMT2AHTR6GABRA1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1192133-B1 N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO INC (US) 2006-11-02 EP disclosed
US-6593346-B2 Substituted 3-(piperidin-1-ylmethyl)cyclopentylamines, useful as modulators of the chemokine receptors CCR-5 and/or CC R-3. MERCK & CO. INC. 2003-07-15 US disclosed
US-6538002-B1 In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3. as antiinflammatory agents MERCK & CO., INC. 2003-03-25 US disclosed
US-20020120146-A1 N-cyclopentyl modulators of chemokine receptor activity MERCK SHARP & DOHME CORP. 2002-08-29 US disclosed
US-6432981-B1 BLOCKS HUMAN IMMUNODEFICIENCY VIRUS (HIV) FROM ENTERING CELLS; AUTOIMMUNE DISEASES; ANTIALLERGENS, ANTIINFLAMMATORY AND ANTIASTHMATIC AGENTS MERCK & CO., INC. 2002-08-13 US disclosed
US-6358979-B1 FOR THERAPY AND PROPHYLAXIS OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, TREATING INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS MERCK & CO., INC. 2002-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120146-A1 N-cyclopentyl modulators of chemokine receptor activity CCR1, CCR3, CCR5 SLC6A2 3939/4885SLC6A3 2186/4885SLC6A4 2303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.